Tocilizumab treatment for new onset refractory status epilepticus
2018; Wiley; Volume: 84; Issue: 6 Linguagem: Inglês
10.1002/ana.25374
ISSN1531-8249
AutoresJin‐Sun Jun, Soon‐Tae Lee, Ryul Kim, Kon Chu, Sang Kun Lee,
Tópico(s)Infectious Encephalopathies and Encephalitis
ResumoWe investigated the therapeutic potential of the interleukin‐6 receptor inhibitor tocilizumab in 7 patients with new onset refractory status epilepticus (NORSE) who remained refractory to conventional immunotherapy with rituximab (n = 5) or without rituximab (n = 2). Status epilepticus (SE) was terminated after 1 or 2 doses of tocilizumab in 6 patients with a median interval of 3 days from the initiation. They had no recurrence of SE during the observation. However, 2 patients experienced severe adverse events related to infection during the tocilizumab therapy. Further prospective controlled studies are warranted to validate the efficacy and safety of tocilizumab in patients with NORSE. Ann Neurol 2018;84:940–945
Referência(s)